In Journal of medical Internet research ; h5-index 88.0
BACKGROUND : With the enlarging stress on hospitals caused by the novel coronavirus disease 2019 (Covid-19) pandemic, the need for home based solutions has become a necessity to support these overwhelmed hospitals.
OBJECTIVE : To compare two non-pharmacological respiratory treatment methods for home isolated Covid-19 patients using a new developed tele-management healthcare system.
METHODS : In this randomized, single-blinded, clinical trial, sixty patients with stage one pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection were treated. Group (A) receiving oxygen therapy with Bi-level positive airway pressure ventilation (BiPAP), and group (B) receiving osteopathic manipulative respiratory and physical therapy techniques. Arterial blood gases of partial pressure of oxygen (PaO2) and partial pressure of carbon dioxide (PaCo2), potential of hydrogen (pH), vital signs (temperature, respiratory rate, oxygen saturation, heart rate and blood pressure), and chest CT scan, were utilized for follow up and for assessment of the course and duration of recovery.
RESULTS : Analysis of the results showed a significant difference between the two groups (p<0.05) with group (A) showing shorter recovery period than group (B) (14.9±1.7 days and 23.9±2.3 days respectively). Significant differences were also observed between base line and final readings in all of the outcome measures in both groups (p<0.05). The post-treatment patient satisfaction with our proposed tele-management healthcare system showed positive response for most of the patients in both groups.
CONCLUSIONS : It was found that home oxygen therapy with BiPAP can be a more effective prophylactic treatment approach than osteopathic manipulative respiratory and physical therapy techniques as it can impede exacerbation of the early stage COVID-19 pneumonia. Tele-management healthcare systems are promising methods to help pandemic-related shortage of hospital beds as they showed reasonable effectiveness and reliability in monitoring and management of the early stage COVID-19 pneumonia patients.
CLINICALTRIAL : ClinicalTrials.gov, identifier: NCT04368923.
Adly Aya Sedky, Adly Mahmoud Sedky, Adly Afnan Sedky